United States securities and exchange commission logo





                              July 21, 2021

       Albert Mitrani
       Chief Executive Officer
       Organicell Regenerative Medicine, Inc.
       4045 Sheridan Avenue, Suite 239
       Miami Beach, FL 33140

                                                        Re: Organicell
Regenerative Medicine, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed July 14, 2021
                                                            File No. 333-257899

       Dear Mr. Mitrani:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comments. In some of our comments, we may ask you to
provide us with
       information so we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1

       General

   1.                                                   We note that your
shares are quoted on the OTC Pink marketplace. Please be advised that
                                                        an at-the-market resale
offering under Rule 415 is not available for registrants quoted on
                                                        the OTC Pink
marketplace. To sell shares at market prices, we require an existing trading
                                                        market for those
shares, and we do not consider the OTC Pink to be such a market for
                                                        purposes of satisfying
Item 501(b)(3) of Regulation S-K. Please revise your prospectus to
                                                        set a fixed price at
which the selling shareholders will offer and sell their shares for the
                                                        duration of the
offering. Please make the appropriate revisions on the front cover page of
                                                        the prospectus and plan
of distribution section.
 Albert Mitrani
Organicell Regenerative Medicine, Inc.
July 21, 2021
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Jennifer Angelini at 202-551-3047 or Sergio Chinos at
202-551-7844 if
you have questions.



                                                           Sincerely,
FirstName LastNameAlbert Mitrani
                                                           Division of
Corporation Finance
Comapany NameOrganicell Regenerative Medicine, Inc.
                                                           Office of
Manufacturing
July 21, 2021 Page 2
cc:       Dale S. Bergman
FirstName LastName